Andreas Kateifides

Andreas Kateifides, MD, PhD, currently serves as Medical Director in Global Medical Sciences at Alexion Pharmaceuticals, Inc., focusing on clinical development for IgA Nephropathy and Lupus Nephritis since August 2022. Prior experience includes a pivotal role as Principal Clinical Scientist at Vertex Pharmaceuticals, specializing in APOL1-mediated kidney diseases, along with several senior positions in clinical science, business operations, and compliance oversight. Educational qualifications include an MBA in Health Sector Management, a PhD in Molecular Medicine, an MSc in Clinical Investigation, and an MD in Medicine, all from institutions like Boston University and the University of Crete. Notable early research involved studying mutant apolipoproteins and their implications in atherogenesis, highlighting a strong foundation in molecular genetics and compliance management throughout a diverse career in the pharmaceutical industry.